Q-omics provides the consensus-scored DEXI profile across patient tissues and cancer cell-line models. DEXI expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, DEXI is differentially expressed in 8, with the highest sampling consensus in UCEC. Additionally, DEXI RNA expression shows 18,410 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, UCEC, and UVM as cancer lineages where DEXI shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEXI — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEXI survival associations across molecular data types. DEXI RNA expression shows survival associations in the most cancer types (28), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEXI RNA expression–survival associations across cancer types. High DEXI expression shows unfavorable associations in BLCA, SKCM and SCLC, but favorable associations in ACC, MESO and LGG. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for DEXI RNA expression.
This table summarizes DEXI tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for DEXI. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEXI shows lower tumor expression in UCEC, PRAD and COAD and higher tumor expression in LIHC, KICH and HNSC. The UCEC box plot shows higher DEXI RNA expression in normal versus tumor tissue (log2 FC = −1.116, t-test p < 0.001).
This table shows molecular features associated with DEXI in patient tissues and cancer cell lines. In patient samples, DEXI shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, DEXI RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
